Global Opioid Induced Constipation Market Size By Active Ingredients(Naloxegol, Lubiprostone, Methylnaltrexone Bromide), By Prescription Type(Over The Counter, Prescription), By End-User(Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geographic Scope And Forecast

Opioid Induced Constipation Market Size And Forecast

Opioid Induced Constipation Market size was valued at USD 1,452.29 Million in 2021 and is projected to reach USD 2,371.32 Million by 2030, growing at a CAGR of 5.9% from 2023 to 2030.

The growth in renal problems can be ascribed to lifestyle changes such as eating calcium and other mineral-rich foods. Several diverse remedies are offered for the sick state, which is leading to market expansion. The Global Opioid Induced Constipation Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Opioid Induced Constipation Market Definition

The activation of enteric -opioid receptors reduces bowel tone and contractility while increasing colonic fluid absorption and anal sphincter tone while decreasing rectal feeling. This results in firmer stools that are more difficult to clear. They ultimately classified OIC as a change in bowel habits following opioid beginning that involves any of the following symptomsdecreased bowel movement frequency, onset or worsening of straining to evacuate stool, a perception of incomplete rectal evacuation, and tougher stool consistency.

Opioid-induced constipation is a condition that is commonly caused by the use of opioid pain relievers such as morphine, codeine, hydrocodone, and others. The therapeutic effect of these medications is highly effective in pain relief, but in the majority of cases, it causes particular types of constipation. The opioids’ attachment to the receptors in the stomach lengthens the time it takes for stool to transit through the gastrointestinal tract. This results in bowel movements being limited to three times a week. As a result, effective therapy is required to alleviate the pain associated with this illness.

Global Opioid Induced Constipation Market Overview

The growth in renal problems can be ascribed to lifestyle changes such as eating calcium and other mineral-rich foods. Several diverse remedies are offered for the sick state, which is leading to market expansion. Lubiprostone is used to treat opioid-induced constipation, with the main indication being chronic idiopathic constipation (CIC). Lubiprostone is expected to overtake methylnaltrexone bromide’s market share. Furthermore, during the forecast period, naloxegol is expected to increase at the fastest CAGR. The medicine is being tested for a variety of patient populations, including pregnant women and children under the age of 17. As a result, future approvals are expected to dominate the market.

The increase in opioid-induced constipation medications delivered through retail pharmacies, as well as the increase in the number of pharmacies in developed nations, creates prospects for market expansion. Furthermore, consumers prefer to buy drugs from retail pharmacies since they are more convenient. Old companies’ patents expiring can provide better chances for emerging market players. Adoption of combination therapy is a major factor driving the growth of the opioid-induced constipation medications market. The patient may develop tolerant and require more and more medicines to attain the desired effect of pain relief. Using opioids for an extended period of time can also lead to dependence. The patient may have withdrawal symptoms such as anxiety, drug cravings, irritability, tremors (shaking), and others after discontinuing the medicine.

Global Opioid Induced Constipation MarketSegmentation Analysis

The Global Opioid Induced Constipation Market is Segmented on the basis of Active Ingredients, Prescription Type, End-User And Geography.

Opioid Induced Constipation Market, By Active Ingredients

• Naloxegol• Lubiprostone• Methylnaltrexone Bromide• Docusate Sodium• Others

On the basis of Active Ingredients, the market is segmented into Naloxegol, Lubiprostone, Methylnaltrexone Bromide, Docusate Sodium, Others. Lubiprostone accounted for the largest market share in the global market owing to benefits and advanatges offered by it. Lubiprostone is used to treat opioid-induced constipation, with the main indication being chronic idiopathic constipation (CIC). Lubiprostone is expected to overtake methylnaltrexone bromide’s market share. Furthermore, during the forecast period, naloxegol is expected to increase at the fastest CAGR. The medicine is being tested for a variety of patient populations, including pregnant women and children under the age of 17.

Opioid Induced Constipation Market, By Prescription Type

• Over The Counter• Prescription

On the basis of Prescription Type, the market is segmented into Over The Counter, Prescription.The Over the counter accounted for the significant market share in the global market due to the rising adoption of OTC and governenent support for this. Stool softener available over-the-counter (OTC)Docusate (Colace) and docusate calcium are two examples (Surfak). They increase the quantity of water in your colon and make it simpler for faeces to pass. Biscacodyl (Ducodyl, Dulcolax) and senna-sennosides are stimulants (Senokot). These stimulate bowel movement by increasing intestinal spasms. Osmotics aid in the movement of fluid through the colon. Oral magnesium hydroxide (Phillips Milk of Magnesia) and polyethylene glycol are two examples (MiraLAX). Mineral oil is a lubricant laxative that also aids in the passage of stool through the colon. It is offered as an over-the-counter (OTC) alternative in both oral and rectal forms.

Opioid Induced Constipation Market, By End-User

• Hospital Pharmacies• Retail Pharmacies• Online Pharmacies

On the basis of end-user, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies. Hospital Pharmacies accounted for the largets market share in the global opioid induced constipation market. Hospital pharmacies contain medications purchased directly from pharmaceutical companies by hospitals and used to treat either outpatients or inpatients. Therapeutic and critical care pharmaceuticals are among the medications available in hospital pharmacy. These medications are used in cardiology, neurology, urology, pathogenic infections, haematological, and dermatology. The major goal of hospital pharmacies is to obtain, store, and sell pharmaceuticals to hospital patients. Individuals are given hospital medications during their hospital-enabled treatment time.

Opioid Induced Constipation Market, By Geography

• North America• Europe• Asia Pacific• Latin America• Middle East and Africa

Based on regional analysis, the Opioid Induced Constipation Market is classified into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America accounted for the largest market share in the global market due to the strong presence of key players and rising R&D activity. Due to increased new research and development on opioid-induced constipation medications industry, Asia-Pacific controls the market. The growing availability of modern healthcare infrastructure and quicker approval of opioid-induced constipation medications as a result of the FDA’s rapid drug approval effort are expected to drive market expansion in this region.

Key Players

The “Global Opioid Induced Constipation Market” study report will provide valuable insight with an emphasis on the global market including some of the major players such as Bayer, Takeda Pharmaceuticals, Sanofi, Salix (Bausch Health), Mallinckrodt, AstraZeneca, Purdue Pharm, Nektar Therapeutics, Progenics Pharmaceuticals, Daiichi Sankyo, GSK, Prestige, Shionogi.

Key Developments

• Takeda has announced that the generic medication Lubiprostone will be available in 2021. Lubiprostone is prescribed to treat both chronic idiopathic constipation and opioid-induced constipation.

• Sandoz Pharmaceutical Company and Shionogi and Co Ltd agreed in 2019 to launch Rizmoic medication in the European market. Rizmoic is a novel medication used to treat opioid-induced constipation in adults.

Ace Matrix Analysis

The Ace Matrix provided in the report would help to understand how the major key players involved in this industry are performing as we provide a ranking for these companies based on various factors such as service features & innovations, scalability, innovation of services, industry coverage, industry reach, and growth roadmap. Based on these factors, we rank the companies into four categories as Active, Cutting Edge, Emerging, and Innovators.

Market Attractiveness

The image of market attractiveness provided would further help to get information about the region that is majorly leading in the Opioid Induced Constipation Market. We cover the major impacting factors that are responsible for driving the industry growth in the given region.

Porter’s Five Forces

The image provided would further help to get information about Porter’s five forces framework providing a blueprint for understanding the behavior of competitors and a player’s strategic positioning in the respective industry. The porter’s five forces model can be used to assess the competitive landscape in Global Opioid Induced Constipation Market gauge the attractiveness of a certain sector, and assess investment possibilities.

Report Scope

Top Trending Reports

Research Methodology of Market Research

To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our .

Reasons to Purchase this Report

• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors• Provision of market value (USD Billion) data for each segment and sub-segment• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled• Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players• The current as well as the future market outlook of the industry with respect to recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions• Includes in-depth analysis of the market of various perspectives through Porter’s five forces analysis• Provides insight into the market through Value Chain• Market dynamics scenario, along with growth opportunities of the market in the years to come• 6-month post-sales analyst support

Customization of the Report

• In case of any  please connect with our sales team, who will ensure that your requirements are met.